Autolus Therapeutics PLCNASDAQ:AUTL
- LAST PRICE3.4800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.4700/ 9
- Ask / Lots3.4800/ 2
- Open / Previous Close3.4800 / 3.4800
- Day Range
- 52 Week Range
- Volume102,603
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AUTL |
|---|---|---|
| 09:32 ET | 10194 | 3.5 |
| 09:34 ET | 14106 | 3.47 |
| 09:36 ET | 200 | 3.455 |
| 09:38 ET | 5100 | 3.48 |
| 09:39 ET | 5408 | 3.52 |
| 09:41 ET | 15445 | 3.5 |
| 09:43 ET | 100 | 3.51 |
| 09:45 ET | 4300 | 3.49 |
| 09:48 ET | 650 | 3.54 |
| 09:50 ET | 500 | 3.53 |
| 09:52 ET | 800 | 3.55 |
| 09:54 ET | 2588 | 3.54 |
| 09:56 ET | 1200 | 3.56 |
| 09:57 ET | 1319 | 3.56 |
| 09:59 ET | 1196 | 3.55 |
| 10:01 ET | 2530 | 3.55 |
| 10:03 ET | 2500 | 3.545 |
| 10:06 ET | 15097 | 3.51 |
| 10:08 ET | 550 | 3.525 |
| 10:10 ET | 4442 | 3.49 |
| 10:12 ET | 200 | 3.48 |
| 10:14 ET | 100 | 3.475 |
Jun 17, 2024
DJ Autolus Therapeutics Price Target Maintained With a $9.00/Share by Needham, from 6:02AM ET on Monday Jun 17, 2024 by Dow Jones
6:02AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 14, 2024
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress, from 7:00AM ET on Friday Jun 14, 2024 by Dow Jones
7:00AM ET on Friday Jun 14, 2024 by Dow Jones
Jun 3, 2024
DJ Autolus Therapeutics Price Target Maintained With a $9.00/Share by Needham, from 6:18AM ET on Monday Jun 03, 2024 by Dow Jones
6:18AM ET on Monday Jun 03, 2024 by Dow Jones
May 31, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Autolus Therapeutics PLC | 925.8M | -2.9x | --- |
Cassava Sciences Inc | 925.5M | -16.4x | --- |
Cullinan Therapeutics Inc | 946.4M | -5.1x | --- |
Tyra Biosciences Inc | 892.1M | -9.8x | --- |
Enliven Therapeutics Inc | 1.0B | -10.7x | --- |
Rapport Therapeutics Inc | 830.3M | -16.2x | --- |
Company Information
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Contact Information
- Headquarters
- The Mediaworks, 191 Wood LaneLONDON, United Kingdom W12 7FP
- Phone
- 203-829-6230
- Fax
- ---
Executives
- Chairman of the Board
- Michael Bonney
- Chief Executive Officer, Executive Director
- Christian Itin
- Founder, Senior Vice President, Chief Scientific Officer
- Martin Pule
- Chief Financial Officer, Senior Vice President
- Lucinda Crabtree
- Chief Operating Officer, Senior Vice President
- Christopher Vann
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $925.8M |
|---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 266.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.10 |
EPS | $-1.21 |
Book Value | --- |
P/E Ratio | -2.9x |
Price/Sales (TTM) | 88.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,670.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
